FATE FATE THERAPEUTICS INC
2026Q1 · CUSIP 31189P102 · Sector: Healthcare & Biotech
Neutral · No signal
Holders
156
Δ holders QoQ
+10
Breadth percentile
Top 29%
Whale holders
81
Δ whales
+4
Inst. holding value
$89M
New positions
27
Closed positions
17
Price momentum (1Q)
—
Put / Call
2/3
Breadth history (34 quarters)
Past Lit Events & Aftermath 8 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2024Q2 | Top 17% | -38.8% | -49.7% |
| 2020Q4 | Top 16% | -24.7% | -13.6% |
| 2020Q2 | Top 6% | +42.2% | +190.6% |
| 2020Q1 | Top 11% | +20.0% | +70.6% |
| 2019Q3 | Top 13% | +105.3% | +116.7% |
| 2019Q2 | Top 11% | -24.0% | +55.8% |
| 2018Q3 | Top 13% | +10.9% | +48.2% |
| 2018Q2 | Top 18% | +15.0% | +30.4% |
Options Sentiment
Put holders
2
QoQ: 0
Call holders
3
QoQ: +2
See methodology →
Fundamentals
PE (TTM)
—
EPS (TTM)
$-1.09
EPS YoY
—
Revenue (TTM)
$0.0B
Revenue YoY
-52.6%
Net margin
—
ROE
-72.3%
Debt ratio
36.9%
FCF (TTM)
-$108M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
As of 2026-03-31 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.